Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.10 USD
+0.90 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.10 USD
+0.90 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum C VGM
Zacks News
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?
by Zacks Equity Research
Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.
Boston Scientific (BSX) Completes First Case With Its PFA System
by Zacks Equity Research
Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.
Ecolab (ECL) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its fourth-quarter sales despite business challenges.
Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands
by Zacks Equity Research
Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.
Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down
by Zacks Equity Research
Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.
Here's Why You Should Invest in Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.
Envista (NVST) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.
STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up
by Zacks Equity Research
STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.
Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down
by Zacks Equity Research
Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.
QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands
by Zacks Equity Research
QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Top Stock Reports for Eli Lilly, Danaher & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Danaher Corporation (DHR) and Citigroup Inc. (C).
PBH vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.
Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.
Boston Scientific (BSX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 5.81% and 3.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Q4 Earnings Due on Jan 31: BSX, TMO & ALGN
by Urmimala Biswas
Medical Products companies' fourth-quarter results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO and ALGN fare this time.
Boston Scientific (BSX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Boston Scientific (BSX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
The Zacks Analyst Blog Highlights Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific
by Zacks Equity Research
Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific are included in this Analyst Blog.
Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN).
PBH or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
What's in Store for Boston Scientific (BSX) in Q4 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.
Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes
by Zacks Equity Research
Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.